drug
avapritinib
Marketedupdated 3mo agoby Blueprint Medicines Corp
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying avapritinib
- phase2(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
- —A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany
- phase1Avapritinib With Decitabine in Patients With SM-AHN
- —Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
- phase4Avapritinib Rollover Study
- phase2A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
- phase2(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
- phase1A Drug-drug Interaction Study of Avapritinib and Midazolam
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 9, 2027
149 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (29)
- Mar 8, 2042method-of-use (U-2726)US 12060354
- Mar 8, 2042method-of-use (U-2726)US 12060354
- Mar 8, 2042method-of-use (U-2726)US 12060354
- Apr 10, 2040compositionUS 11964980
- Apr 10, 2040compositionUS 11964980
- Apr 10, 2040compositionUS 11964980
- Apr 10, 2040compositionUS 11964980
- Apr 10, 2040compositionUS 11964980
- Apr 10, 2040method-of-use (U-3168)US 11999744
- Apr 10, 2040method-of-use (U-3168)US 11999744
- Apr 10, 2040method-of-use (U-3506)US 11999744
- Apr 10, 2040method-of-use (U-3168)US 11999744
- Apr 10, 2040method-of-use (U-3506)US 12252494
- Oct 15, 2034compositionUS 11827642
- Oct 15, 2034compositionUS 9200002
- Oct 15, 2034compositionUS 9200002
- Oct 15, 2034compositionUS 9200002
- Oct 15, 2034compositionUS 9200002
- Oct 15, 2034compositionUS 9200002
- Oct 15, 2034compositionUS 9944651
- Oct 15, 2034compositionUS 9944651
- Oct 15, 2034compositionUS 9944651
- Oct 15, 2034compositionUS 9944651
- Oct 15, 2034compositionUS 9944651
- Oct 15, 2034compositionUS 9994575
- Oct 15, 2034compositionUS 9994575
- Oct 15, 2034compositionUS 9994575
- Oct 15, 2034compositionUS 9994575
- Oct 15, 2034compositionUS 9994575
FDA exclusivities (16)
- May 22, 2030ODE-434Orphan Drug (7y)3.8y
- May 22, 2030ODE-434Orphan Drug (7y)3.8y
- May 22, 2030ODE-434Orphan Drug (7y)3.8y
- May 22, 2030ODE-434Orphan Drug (7y)3.8y
- May 22, 2030ODE-434Orphan Drug (7y)3.8y
- Jun 16, 2028ODE-356Orphan Drug (7y)1.8y
- Jun 16, 2028ODE-356Orphan Drug (7y)1.8y
- Jun 16, 2028ODE-356Orphan Drug (7y)1.8y
- Jun 16, 2028ODE-356Orphan Drug (7y)1.8y
- Jun 16, 2028ODE-356Orphan Drug (7y)1.8y
- Jan 9, 2027ODE-366Orphan Drug (7y)149d
- Jan 9, 2027ODE-366Orphan Drug (7y)149d
- Jan 9, 2027ODE-366Orphan Drug (7y)149d
- Jan 9, 2027ODE-366Orphan Drug (7y)149d
- Jan 9, 2027ODE-366Orphan Drug (7y)149d
- May 22, 2026I-912Indication (3y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 36m ago
Found something off?
comments(0)
5-min edit window · permanent after that